enGene Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
enGene Therapeutics Inc. (ENGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.84 million shares for the 9-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-09-08
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-07-31 was 676.45K shares, a 33.46% decline year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-04-30 was 0.00 shares, a 100.00% decline year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-01-31 was 3.16M shares, a 1.73% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-10-31 was 657.95K shares, a 16.25% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 4.93M shares, a 37.19% increase from fiscal 2024.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.59M shares, a 174.54% increase from fiscal 2023.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.31M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-07-31 | 676.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-08 | 676.45K shares derived: sum of 2 quarters · filed 2026-09-08 | 3.84M shares 10-Q · filed 2026-09-08 | 4.50M shares derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-06-15 | 3.16M shares 10-Q · filed 2026-06-15 | 3.82M shares derived: sum of 3 quarters · filed 2026-06-15 | 4.84M shares derived: sum of 4 quarters · filed 2026-06-15 |
| 2026-01-31 | 3.16M shares 10-Q · filed 2026-03-09 | 3.82M shares derived: sum of 2 quarters · filed 2026-03-09 | 4.84M shares derived: sum of 3 quarters · filed 2026-03-09 | 4.98M shares derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-10-31 | 657.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | 1.67M shares derived: sum of 2 quarters · filed 2025-12-22 | 1.82M shares derived: sum of 3 quarters · filed 2025-12-22 | 4.93M shares 10-K · filed 2025-12-22 |
| 2025-07-31 | 1.02M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-09-11 | 1.16M shares derived: sum of 2 quarters · filed 2025-09-11 | 4.27M shares 10-Q · filed 2025-09-11 | 4.83M shares derived: sum of 4 quarters · filed 2025-09-11 |
| 2025-04-30 | 144.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-06-12 | 3.25M shares 10-Q · filed 2025-06-12 | 3.82M shares derived: sum of 3 quarters · filed 2025-06-12 | 5.51M shares derived: sum of 4 quarters · filed 2025-06-12 |
| 2025-01-31 | 3.11M shares 10-Q · filed 2025-03-10 | 3.67M shares derived: sum of 2 quarters · filed 2025-03-10 | 5.37M shares derived: sum of 3 quarters · filed 2025-03-10 | 6.11M shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-10-31 | 566.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | 2.26M shares derived: sum of 2 quarters · filed 2024-12-19 | 3.00M shares derived: sum of 3 quarters · filed 2024-12-19 | 3.59M shares 10-K · filed 2024-12-19 |
| 2024-07-31 | 1.69M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-09-10 | 2.44M shares derived: sum of 2 quarters · filed 2024-09-10 | 3.03M shares 10-Q · filed 2024-09-10 | |
| 2024-04-30 | 743.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-06-14 | 1.33M shares 10-Q · filed 2024-06-14 | ||
| 2024-01-31 | 588.00K shares 10-Q · filed 2024-03-11 | |||
| 2023-10-31 | 1.31M shares 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |